5月28日上午，港股新上市公司派格生物医药-B（02565）盘中大跌5.02%，延续了上市首日的跌势，引发投资者关注。
派格生物医药于5月27日在港交所正式挂牌上市，发行价为15.6港元。然而，上市首日即遭遇破发，收盘价为11.66港元，大跌25.9%。截至首日收盘，公司市值约为32.55亿港元。
派格生物医药成立于2008年，专注于自主研究及开发慢性病创新疗法，重点关注内分泌代谢领域。目前，公司有6款候选产品，但尚未有商业化产品。其中，进展最快的是一款GLP-1激动剂PB-119，其针对糖尿病的单药和联合疗法已提交上市注册申请。
分析人士认为，派格生物医药股价持续下跌，可能与公司尚未盈利且产品未实现商业化有关。不过，该公司核心产品PB-119前景被看好，若未来获批上市，有望改善公司业绩，扭转市场对其估值预期。投资者仍需密切关注公司后续产品研发进展和市场表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.